The Meiji Group has earned an excellent reputation for many products, including the antidepressant drug, REFLEX. It also specializes in developing drugs for treating infectious diseases and disorders of the central nervous system.

While committed to supplying these products to as many people as possible, the Group recognized the need to expand its product lineup with more effective drugs and to ensure a stable supply of those products. Toward that end, it began focusing on producing generic drugs in 1998. An example of these products was AMLODIPINE MEIJI, released in 2008. It was the first generic drug to feature "Meiji" in the name, and all processes, from formulation development to sales, were handled in-house. Furthermore, Meiji Holdings acquired business units of other manufacturers, including a vaccine business, and made KM Biologics a consolidated subsidiary in 2018. As a result, the Group bolstered its development capabilities in biomedicine and, after mainly offering pharmaceuticals, expanded its product lineup with both preventative and therapeutic drugs.